<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976466</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT03976466</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors.</brief_title>
  <acronym>Stimulan</acronym>
  <official_title>Application of Antibiotic Loaded Calcium Sulfate as Prophylaxis for Patients With Non Modifiable Risk Factors for Periprosthetic Joint Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Regional Tlalnepantla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Regional Tlalnepantla</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the prophylactic effect of calcium sulfate beads loaded with antibiotic in&#xD;
      patients with non-modifiable risk factors that will undergo a hip or knee joint replacement,&#xD;
      comparing with a control group.&#xD;
&#xD;
      To know the economic cost generated in antibiotic prophylaxis with calcium sulfate beads in&#xD;
      patients undergoing hip or knee joint replacement with non-modifiable risk factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since joint replacement procedures have been successful in recent decades, every year the&#xD;
      number of implanted prostheses is increasing, however, at the same time, orthopaedic surgeons&#xD;
      also find complications inherent to this surgery, where peri-prosthetic infection results to&#xD;
      be the most devastating. In order to find a solution to this terrible complication,&#xD;
      prophylactic and therapeutic measures have been implemented, emerging techniques where the&#xD;
      application of local antibiotics in the surgical site has turned out to be a promising&#xD;
      concept. It has been shown that the non-modifiable risk factors of patients undergoing joint&#xD;
      replacement surgery increase the risk of infection rate. Therefore, the identification of&#xD;
      risk factors, decolonization and the prophylactic administration of antibiotics allow an&#xD;
      effective reduction of periprosthetic infection. In order to reduce and, as far as posible,&#xD;
      avoid periprosthetic infections in participants undergo knee or hip joint replacement with&#xD;
      non-modifiable risk factors, the prophylactic use of calcium sulphate loaded with antibiotic&#xD;
      for local application is proposed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial. Study participants are randomly assigned to one of two groups: the experimental group receiving the Calcium sulfate beds with antibiotics and a comparison group (control) which receives a conventional prophylactic therapy.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>No participant will know during the study in which group will be assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Partipants Achieving a Lower Hip or Knee Periprosthetic Joint Infection Rate With Local Versus Conventional Intravenous Antibiotic Prophilaxys, Measured With CRP, ERS in Serum and Sinovial Fluid Leukocytes , Over the 12-week Observation Period.</measure>
    <time_frame>Day 5, Weeks 4, 8, and 12</time_frame>
    <description>Acute periprosthetic knee or hip infection was determined using CRP and ESR serum biomarkers, which are the most commonly published serum biomarkers in periprosthetic joint infection literature. The cut off point for CRP was considered 93mg/L and 44mm/hr for ESR. The serum biomarker sample was taken and evaluated on day 5 and weeks 4, 8 and 12. Leukocytes in synovial fluid are among the criteria for definition of periprosthetic joint infection with a cut off point above 12,800 cells/µL and were only included if serum biomarkers were elevated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay as an Indicator of the Hospital Economic Burden</measure>
    <time_frame>Surgical procedure day to hospital discharge.</time_frame>
    <description>The length of stay is an important indicator of efficiency and hospital economic burden. The reduction in number of hospitalization days results in lower risk of infection and less medication side effects and decreased need of hospital supplies. The difference in the average days of hospitalization between both groups indirectly represents the economic cost spent by the hospital.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Calcium sulfate Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Antibiotic local prophylaxis with medicated calcium sulfate beads</intervention_name>
    <description>Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection</description>
    <arm_group_label>Calcium sulfate Group</arm_group_label>
    <other_name>Hip or Knee Joint Replacement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Classical parenteral antibiotic prophylaxis</intervention_name>
    <description>Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Hip pr Knee Joint Replacement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with fracture or osteoarthrosis of the hip or knee that require treatment by&#xD;
             joint replacement.&#xD;
&#xD;
          -  patients who have any of the Non-Modifiable Risk Factors prior to surgery or during&#xD;
             transoperative period.&#xD;
&#xD;
          -  Patients entitled to the ISSEMyM (Instituto de Seguridad Social del Estado de Mexico y&#xD;
             Municipios)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that lose their validity of institutional rights and do not follow up&#xD;
&#xD;
          -  Patients who die during the study due to other causes not related to the orthopedic&#xD;
             procedure.&#xD;
&#xD;
          -  Patients who do not have any of the risk factors for periprosthetic infection&#xD;
&#xD;
          -  Patients allergic to vancomycin or ceftriaxone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HOSPITAL REGIONAL TLALNEPANTLA ISSEMyM</name>
      <address>
        <city>Tlalnepantla</city>
        <zip>54090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ong KL, Kurtz SM, Lau E, Bozic KJ, Berry DJ, Parvizi J. Prosthetic joint infection risk after total hip arthroplasty in the Medicare population. J Arthroplasty. 2009 Sep;24(6 Suppl):105-9. doi: 10.1016/j.arth.2009.04.027. Epub 2009 Jun 2.</citation>
    <PMID>19493644</PMID>
  </reference>
  <reference>
    <citation>Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008 Jul;466(7):1710-5. doi: 10.1007/s11999-008-0209-4. Epub 2008 Apr 18.</citation>
    <PMID>18421542</PMID>
  </reference>
  <reference>
    <citation>Wahl P, Guidi M, Benninger E, Rönn K, Gautier E, Buclin T, Magnin JL, Livio F. The levels of vancomycin in the blood and the wound after the local treatment of bone and soft-tissue infection with antibiotic-loaded calcium sulphate as carrier material. Bone Joint J. 2017 Nov;99-B(11):1537-1544. doi: 10.1302/0301-620X.99B11.BJJ-2016-0298.R3.</citation>
    <PMID>29092996</PMID>
  </reference>
  <reference>
    <citation>Wahl P, Livio F, Jacobi M, Gautier E, Buclin T. Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Arch Orthop Trauma Surg. 2011 May;131(5):657-62. doi: 10.1007/s00402-010-1192-2. Epub 2010 Oct 12.</citation>
    <PMID>20938669</PMID>
  </reference>
  <reference>
    <citation>Reed EE, Johnston J, Severing J, Stevenson KB, Deutscher M. Nephrotoxicity Risk Factors and Intravenous Vancomycin Dosing in the Immediate Postoperative Period Following Antibiotic-Impregnated Cement Spacer Placement. Ann Pharmacother. 2014 Aug;48(8):962-969. Epub 2014 May 13.</citation>
    <PMID>24823910</PMID>
  </reference>
  <reference>
    <citation>Horii C, Yamazaki T, Oka H, Azuma S, Ogihara S, Okazaki R, Kawamura N, Takano Y, Morii J, Takeshita Y, Maruyama T, Yamakawa K, Murakami M, Oshima Y, Tanaka S. Does intrawound vancomycin powder reduce surgical site infection after posterior instrumented spinal surgery? A propensity score-matched analysis. Spine J. 2018 Dec;18(12):2205-2212. doi: 10.1016/j.spinee.2018.04.015. Epub 2018 Apr 26.</citation>
    <PMID>29705336</PMID>
  </reference>
  <reference>
    <citation>Sweet FA, Roh M, Sliva C. Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes. Spine (Phila Pa 1976). 2011 Nov 15;36(24):2084-8. doi: 10.1097/BRS.0b013e3181ff2cb1.</citation>
    <PMID>21304438</PMID>
  </reference>
  <reference>
    <citation>Zebala LP, Chuntarapas T, Kelly MP, Talcott M, Greco S, Riew KD. Intrawound vancomycin powder eradicates surgical wound contamination: an in vivo rabbit study. J Bone Joint Surg Am. 2014 Jan 1;96(1):46-51. doi: 10.2106/JBJS.L.01257.</citation>
    <PMID>24382724</PMID>
  </reference>
  <reference>
    <citation>Whiteside LA, Peppers M, Nayfeh TA, Roy ME. Methicillin-resistant Staphylococcus aureus in TKA treated with revision and direct intra-articular antibiotic infusion. Clin Orthop Relat Res. 2011 Jan;469(1):26-33. doi: 10.1007/s11999-010-1313-9.</citation>
    <PMID>20390472</PMID>
  </reference>
  <reference>
    <citation>Buchholz HW, Engelbrecht H. [Depot effects of various antibiotics mixed with Palacos resins]. Chirurg. 1970 Nov;41(11):511-5. German.</citation>
    <PMID>5487941</PMID>
  </reference>
  <reference>
    <citation>Bennett-Guerrero E, Pappas TN, Koltun WA, Fleshman JW, Lin M, Garg J, Mark DB, Marcet JE, Remzi FH, George VV, Newland K, Corey GR; SWIPE 2 Trial Group. Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med. 2010 Sep 9;363(11):1038-49. doi: 10.1056/NEJMoa1000837. Epub 2010 Aug 4. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.</citation>
    <PMID>20825316</PMID>
  </reference>
  <reference>
    <citation>Birgand G, Radu C, Alkhoder S, Al Attar N, Raffoul R, Dilly MP, Nataf P, Lucet JC. Does a gentamicin-impregnated collagen sponge reduce sternal wound infections in high-risk cardiac surgery patients? Interact Cardiovasc Thorac Surg. 2013 Feb;16(2):134-41. doi: 10.1093/icvts/ivs449. Epub 2012 Oct 31.</citation>
    <PMID>23115102</PMID>
  </reference>
  <reference>
    <citation>KOVACEVIC B. [Problem of hematogenous osteomyelitis]. Langenbecks Arch Klin Chir Ver Dtsch Z Chir. 1953;276:432-43. Undetermined Language.</citation>
    <PMID>13143827</PMID>
  </reference>
  <reference>
    <citation>Fischer G, Seidler W. [Results in the treatment of osteomyelitic bone cavities using antibiotic gypsum medullary plombage]. Dtsch Gesundheitsw. 1971 Nov 4;26(45):2105-7. German.</citation>
    <PMID>5145654</PMID>
  </reference>
  <reference>
    <citation>Mackey D, Varlet A, Debeaumont D. Antibiotic loaded plaster of Paris pellets: an in vitro study of a possible method of local antibiotic therapy in bone infection. Clin Orthop Relat Res. 1982 Jul;(167):263-8.</citation>
    <PMID>7094471</PMID>
  </reference>
  <reference>
    <citation>Varlet A, Dauchy P. [Plaster of Paris pellets containing antibiotics in the treatment of bone infection. New combinations of plaster with antibiotics]. Rev Chir Orthop Reparatrice Appar Mot. 1983;69(3):239-44. French.</citation>
    <PMID>6224275</PMID>
  </reference>
  <reference>
    <citation>Dahners LE, Funderburk CH. Gentamicin-loaded plaster of Paris as a treatment of experimental osteomyelitis in rabbits. Clin Orthop Relat Res. 1987 Jun;(219):278-82.</citation>
    <PMID>3581579</PMID>
  </reference>
  <reference>
    <citation>Evrard J, Kerri O, Martini M, Conort O. [Treatment of bone infection by plaster of Paris pellets impregnated with antibiotics]. Pathol Biol (Paris). 1990 Jun;38(5 ( Pt 2)):543-7. French.</citation>
    <PMID>2385452</PMID>
  </reference>
  <reference>
    <citation>Mousset B, Benoit MA, Bouillet R, Gillard J. [Plaster of Paris: a carrier for antibiotics in the treatment of bone infections]. Acta Orthop Belg. 1993;59(3):239-48. French.</citation>
    <PMID>8237338</PMID>
  </reference>
  <reference>
    <citation>Sulo I. [Gentamycin impregnated plaster beads in the treatment of bone infection]. Rev Chir Orthop Reparatrice Appar Mot. 1993;79(4):299-305. French.</citation>
    <PMID>8159845</PMID>
  </reference>
  <reference>
    <citation>Gitelis S, Brebach GT. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg (Hong Kong). 2002 Jun;10(1):53-60.</citation>
    <PMID>12401922</PMID>
  </reference>
  <reference>
    <citation>Meza-López LR, Cigarroa-López JA, Hernández-Meneses S, Castán-Flores DA, Mendoza-Zavala GH, Barragán-Zamora JA, Carrillo-Muñoz A, Munguía-Canales DA. [Dissolvable and extended release antibiotic beads in mediastinoscopic management of mediastinitis after heart transplantation]. Arch Cardiol Mex. 2017 Apr - Jun;87(2):182-186. doi: 10.1016/j.acmx.2017.01.006. Epub 2017 Mar 2. Spanish.</citation>
    <PMID>28259393</PMID>
  </reference>
  <reference>
    <citation>Aiken SS, Cooper JJ, Florance H, Robinson MT, Michell S. Local release of antibiotics for surgical site infection management using high-purity calcium sulfate: an in vitro elution study. Surg Infect (Larchmt). 2015 Feb;16(1):54-61. doi: 10.1089/sur.2013.162. Epub 2014 Aug 22.</citation>
    <PMID>25148101</PMID>
  </reference>
  <reference>
    <citation>Howlin RP, Brayford MJ, Webb JS, Cooper JJ, Aiken SS, Stoodley P. Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections. Antimicrob Agents Chemother. 2015 Jan;59(1):111-20. doi: 10.1128/AAC.03676-14. Epub 2014 Oct 13.</citation>
    <PMID>25313221</PMID>
  </reference>
  <reference>
    <citation>Howlin RP, Winnard C, Angus EM, Frapwell CJ, Webb JS, Cooper JJ, Aiken SS, Bishop JY, Stoodley P. Prevention of Propionibacterium acnes biofilm formation in prosthetic infections in vitro. J Shoulder Elbow Surg. 2017 Apr;26(4):553-563. doi: 10.1016/j.jse.2016.09.042. Epub 2016 Dec 15.</citation>
    <PMID>27989720</PMID>
  </reference>
  <reference>
    <citation>Howlin RP, Winnard C, Frapwell CJ, Webb JS, Cooper JJ, Aiken SS, Stoodley P. Biofilm prevention of gram-negative bacterial pathogens involved in periprosthetic infection by antibiotic-loaded calcium sulfate beads in vitro. Biomed Mater. 2016 Dec 2;12(1):015002.</citation>
    <PMID>27910828</PMID>
  </reference>
  <reference>
    <citation>Kallala R, Harris WE, Ibrahim M, Dipane M, McPherson E. Use of Stimulan absorbable calcium sulphate beads in revision lower limb arthroplasty: Safety profile and complication rates. Bone Joint Res. 2018 Nov 3;7(10):570-579. doi: 10.1302/2046-3758.710.BJR-2017-0319.R1. eCollection 2018 Oct.</citation>
    <PMID>30464837</PMID>
  </reference>
  <reference>
    <citation>Lum ZC, Pereira GC. Local bio-absorbable antibiotic delivery in calcium sulfate beads in hip and knee arthroplasty. J Orthop. 2018 May 7;15(2):676-678. doi: 10.1016/j.jor.2018.05.001. eCollection 2018 Jun.</citation>
    <PMID>29881219</PMID>
  </reference>
  <reference>
    <citation>Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012 Sep;27(8 Suppl):61-5.e1. doi: 10.1016/j.arth.2012.02.022. Epub 2012 May 2.</citation>
    <PMID>22554729</PMID>
  </reference>
  <reference>
    <citation>Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplasty. 2010 Sep;25(6 Suppl):103-7. doi: 10.1016/j.arth.2010.04.011. Epub 2010 May 31.</citation>
    <PMID>20570103</PMID>
  </reference>
  <reference>
    <citation>Parvizi J, Azzam K, Ghanem E, Austin MS, Rothman RH. Periprosthetic infection due to resistant staphylococci: serious problems on the horizon. Clin Orthop Relat Res. 2009 Jul;467(7):1732-9. doi: 10.1007/s11999-009-0857-z. Epub 2009 May 1.</citation>
    <PMID>19408061</PMID>
  </reference>
  <reference>
    <citation>Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008 Oct;23(7):984-91. doi: 10.1016/j.arth.2007.10.017. Epub 2008 Apr 10.</citation>
    <PMID>18534466</PMID>
  </reference>
  <reference>
    <citation>Almeida Herrero F, López Lozano R, Silvestre Muñoz A. [Descriptive analysis of C-Reactive values after uncomplicated total hip and knee arthroplasty]. Acta Ortop Mex. 2008 Mar-Apr;22(2):80-4. Spanish.</citation>
    <PMID>18669307</PMID>
  </reference>
  <reference>
    <citation>Bilgen O, Atici T, Durak K, Karaeminoğullari, Bilgen MS. C-reactive protein values and erythrocyte sedimentation rates after total hip and total knee arthroplasty. J Int Med Res. 2001 Jan-Feb;29(1):7-12.</citation>
    <PMID>11277348</PMID>
  </reference>
  <reference>
    <citation>Greidanus NV, Masri BA, Garbuz DS, Wilson SD, McAlinden MG, Xu M, Duncan CP. Use of erythrocyte sedimentation rate and C-reactive protein level to diagnose infection before revision total knee arthroplasty. A prospective evaluation. J Bone Joint Surg Am. 2007 Jul;89(7):1409-16.</citation>
    <PMID>17606776</PMID>
  </reference>
  <reference>
    <citation>Hashmi FR, Barlas K, Mann CF, Howell FR. Staged bilateral hip or knee arthroplasties. J Orthop Surg (Hong Kong). 2007 Aug;15(2):159-62.</citation>
    <PMID>17709852</PMID>
  </reference>
  <reference>
    <citation>Larsson S, Thelander U, Friberg S. C-reactive protein (CRP) levels after elective orthopedic surgery. Clin Orthop Relat Res. 1992 Feb;(275):237-42.</citation>
    <PMID>1735220</PMID>
  </reference>
  <reference>
    <citation>Nazem K, Motififard M, Yousefian M. Variations in ESR and CRP in total knee arthroplasty and total hip arthroplasty in Iranian patients from 2009 to 2011. Adv Biomed Res. 2016 Aug 30;5:148. doi: 10.4103/2277-9175.187403. eCollection 2016.</citation>
    <PMID>27656617</PMID>
  </reference>
  <reference>
    <citation>Park KK, Kim TK, Chang CB, Yoon SW, Park KU. Normative Temporal Values of CRP and ESR in Unilateral and Staged Bilateral TKA. Clin Orthop Relat Res. 2008 Jan;466(1):179-88. doi: 10.1007/s11999-007-0001-x. Epub 2008 Jan 3.</citation>
    <PMID>18196391</PMID>
  </reference>
  <reference>
    <citation>Parvizi J, Ghanem E, Sharkey P, Aggarwal A, Burnett RS, Barrack RL. Diagnosis of infected total knee: findings of a multicenter database. Clin Orthop Relat Res. 2008 Nov;466(11):2628-33. doi: 10.1007/s11999-008-0471-5. Epub 2008 Sep 10.</citation>
    <PMID>18781372</PMID>
  </reference>
  <reference>
    <citation>White J, Kelly M, Dunsmuir R. C-reactive protein level after total hip and total knee replacement. J Bone Joint Surg Br. 1998 Sep;80(5):909-11.</citation>
    <PMID>9768908</PMID>
  </reference>
  <reference>
    <citation>Yi PH, Cross MB, Moric M, Sporer SM, Berger RA, Della Valle CJ. The 2013 Frank Stinchfield Award: Diagnosis of infection in the early postoperative period after total hip arthroplasty. Clin Orthop Relat Res. 2014 Feb;472(2):424-9. doi: 10.1007/s11999-013-3089-1.</citation>
    <PMID>23884798</PMID>
  </reference>
  <reference>
    <citation>Zimmerli W. Clinical presentation and treatment of orthopaedic implant-associated infection. J Intern Med. 2014 Aug;276(2):111-9. doi: 10.1111/joim.12233.</citation>
    <PMID>24605880</PMID>
  </reference>
  <reference>
    <citation>Arnold WV, Shirtliff ME, Stoodley P. Bacterial biofilms and periprosthetic infections. J Bone Joint Surg Am. 2013 Dec 18;95(24):2223-9.</citation>
    <PMID>24498639</PMID>
  </reference>
  <reference>
    <citation>McConoughey SJ, Howlin R, Granger JF, Manring MM, Calhoun JH, Shirtliff M, Kathju S, Stoodley P. Biofilms in periprosthetic orthopedic infections. Future Microbiol. 2014;9(8):987-1007. doi: 10.2217/fmb.14.64. Review. Erratum in: Future Microbiol. 2014;9(10):1234.</citation>
    <PMID>25302955</PMID>
  </reference>
  <reference>
    <citation>Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol. 2018 Jul;16(7):397-409. doi: 10.1038/s41579-018-0019-y. Review.</citation>
    <PMID>29720707</PMID>
  </reference>
  <reference>
    <citation>Klemm K. [Gentamicin-PMMA-beads in treating bone and soft tissue infections (author's transl)]. Zentralbl Chir. 1979;104(14):934-42. German.</citation>
    <PMID>494865</PMID>
  </reference>
  <reference>
    <citation>Nelson CL, Jones RB, Wingert NC, Foltzer M, Bowen TR. Sonication of antibiotic spacers predicts failure during two-stage revision for prosthetic knee and hip infections. Clin Orthop Relat Res. 2014 Jul;472(7):2208-14. Erratum in: Clin Orthop Relat Res. 2014 Jul;472(7):2307.</citation>
    <PMID>24658903</PMID>
  </reference>
  <reference>
    <citation>Neut D, van de Belt H, Stokroos I, van Horn JR, van der Mei HC, Busscher HJ. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J Antimicrob Chemother. 2001 Jun;47(6):885-91.</citation>
    <PMID>11389124</PMID>
  </reference>
  <reference>
    <citation>Tunney MM, Ramage G, Patrick S, Nixon JR, Murphy PG, Gorman SP. Antimicrobial susceptibility of bacteria isolated from orthopedic implants following revision hip surgery. Antimicrob Agents Chemother. 1998 Nov;42(11):3002-5.</citation>
    <PMID>9797241</PMID>
  </reference>
  <reference>
    <citation>Chang CC, Merritt K. Microbial adherence on poly(methyl methacrylate) (PMMA) surfaces. J Biomed Mater Res. 1992 Feb;26(2):197-207.</citation>
    <PMID>1569113</PMID>
  </reference>
  <reference>
    <citation>Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother. 2006 Jan;50(1):55-61.</citation>
    <PMID>16377667</PMID>
  </reference>
  <reference>
    <citation>van de Belt H, Neut D, Schenk W, van Horn JR, van der Mei HC, Busscher HJ. Infection of orthopedic implants and the use of antibiotic-loaded bone cements. A review. Acta Orthop Scand. 2001 Dec;72(6):557-71. Review.</citation>
    <PMID>11817870</PMID>
  </reference>
  <reference>
    <citation>Winkler H. Treatment of chronic orthopaedic infection. EFORT Open Rev. 2017 May 11;2(5):110-116. doi: 10.1302/2058-5241.2.160063. eCollection 2017 May.</citation>
    <PMID>28630748</PMID>
  </reference>
  <reference>
    <citation>Zhu Y, Zhang F, Chen W, Liu S, Zhang Q, Zhang Y. Risk factors for periprosthetic joint infection after total joint arthroplasty: a systematic review and meta-analysis. J Hosp Infect. 2015 Feb;89(2):82-9. doi: 10.1016/j.jhin.2014.10.008. Epub 2014 Dec 4. Review.</citation>
    <PMID>25575769</PMID>
  </reference>
  <reference>
    <citation>Cordero-Ampuero J, de Dios M. What are the risk factors for infection in hemiarthroplasties and total hip arthroplasties? Clin Orthop Relat Res. 2010 Dec;468(12):3268-77. doi: 10.1007/s11999-010-1411-8.</citation>
    <PMID>20544319</PMID>
  </reference>
  <reference>
    <citation>Namba RS, Inacio MC, Paxton EW. Risk factors associated with deep surgical site infections after primary total knee arthroplasty: an analysis of 56,216 knees. J Bone Joint Surg Am. 2013 May 1;95(9):775-82. doi: 10.2106/JBJS.L.00211.</citation>
    <PMID>23636183</PMID>
  </reference>
  <reference>
    <citation>Neut D, van de Belt H, van Horn JR, van der Mei HC, Busscher HJ. Residual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of implantation. Biomaterials. 2003 May;24(10):1829-31.</citation>
    <PMID>12593965</PMID>
  </reference>
  <reference>
    <citation>Wilson KJ, Cierny G, Adams KR, Mader JT. Comparative evaluation of the diffusion of tobramycin and cefotaxime out of antibiotic-impregnated polymethylmethacrylate beads. J Orthop Res. 1988;6(2):279-86.</citation>
    <PMID>3278081</PMID>
  </reference>
  <reference>
    <citation>Ribeiro M, Monteiro FJ, Ferraz MP. Infection of orthopedic implants with emphasis on bacterial adhesion process and techniques used in studying bacterial-material interactions. Biomatter. 2012 Oct-Dec;2(4):176-94. doi: 10.4161/biom.22905. Review.</citation>
    <PMID>23507884</PMID>
  </reference>
  <reference>
    <citation>Rimondini L, Fini M, Giardino R. The microbial infection of biomaterials: A challenge for clinicians and researchers. A short review. J Appl Biomater Biomech. 2005 Jan-Apr;3(1):1-10.</citation>
    <PMID>20799234</PMID>
  </reference>
  <reference>
    <citation>Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are We Winning or Losing the Battle With Periprosthetic Joint Infection: Trends in Periprosthetic Joint Infection and Mortality Risk for the Medicare Population. J Arthroplasty. 2018 Oct;33(10):3238-3245. doi: 10.1016/j.arth.2018.05.042. Epub 2018 Jun 1.</citation>
    <PMID>29914821</PMID>
  </reference>
  <reference>
    <citation>Aujla RS, Esler CN. Total Knee Arthroplasty for Osteoarthritis in Patients Less Than Fifty-Five Years of Age: A Systematic Review. J Arthroplasty. 2017 Aug;32(8):2598-2603.e1. doi: 10.1016/j.arth.2017.02.069. Epub 2017 Mar 3. Review.</citation>
    <PMID>28456563</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <results_first_submitted>July 19, 2020</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Regional Tlalnepantla</investigator_affiliation>
    <investigator_full_name>Julio Carlos Velez de Lachica</investigator_full_name>
    <investigator_title>Md. High Specialty Associate Professor of the Joint Surgery Course.</investigator_title>
  </responsible_party>
  <keyword>Periprosthetic Joint Infection</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Joint Replacement</keyword>
  <keyword>Calcium Sulfate Beads</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03976466/Prot_SAP_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Inclusion critera for patients to complete enrolled protocol were: patients over 60 years old, no history of cephalosporine allergy, to have any of the non-modifiable risk factors, patients who accept blood transfusion. Patientes who are institutional entitled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Calcium Sulfate Study Group</title>
          <description>Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement&#xD;
Antibiotic local prophylaxis with medicated calcium sulfate beads: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection. 3g of vancomycin mixed with Stimulan Kit (Biocomposites Ltd, United Kingdom) which includes 10 cc (20 g) of calcium sulfate hemihydrate powder</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement&#xD;
Classical parenteral antibiotic prophylaxis: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection. 750 mgs of Intra Venous Ceftriaxone 20 minutes before joint replacement surgery and every 8 hours for 24 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcium Sulfate Group</title>
          <description>Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement&#xD;
Antibiotic local prophylaxis with medicated calcium sulfate beads: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement&#xD;
Classical parenteral antibiotic prophylaxis: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.9" spread="8.14"/>
                    <measurement group_id="B2" value="77.3" spread="8.9"/>
                    <measurement group_id="B3" value="76.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>non-modifiable risk factors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Body Mass Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound Drain, dehiscence or surgical active infecti</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of nosocomial infection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolonged surgical time</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decompensated Type 2 Diabetes Mellitus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Albumin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rheumatoid Arthritis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood transfusion Transoperative Bleeding</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of prosthetic surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunosuppression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corticosteroid Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of Joint Prosthesis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>KNEE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HIP</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Periprosthetic Joint Infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>With periprosthetic infection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without periprosthetic infection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Partipants Achieving a Lower Hip or Knee Periprosthetic Joint Infection Rate With Local Versus Conventional Intravenous Antibiotic Prophilaxys, Measured With CRP, ERS in Serum and Sinovial Fluid Leukocytes , Over the 12-week Observation Period.</title>
        <description>Acute periprosthetic knee or hip infection was determined using CRP and ESR serum biomarkers, which are the most commonly published serum biomarkers in periprosthetic joint infection literature. The cut off point for CRP was considered 93mg/L and 44mm/hr for ESR. The serum biomarker sample was taken and evaluated on day 5 and weeks 4, 8 and 12. Leukocytes in synovial fluid are among the criteria for definition of periprosthetic joint infection with a cut off point above 12,800 cells/µL and were only included if serum biomarkers were elevated.</description>
        <time_frame>Day 5, Weeks 4, 8, and 12</time_frame>
        <population>Patients who agreed to join the study and who met the selection criteria. After 3 moths presents or not periprosthetic joint infection.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement&#xD;
Classical parenteral antibiotic prophylaxis: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection</description>
          </group>
          <group group_id="O2">
            <title>Calcium Sulfate Group</title>
            <description>Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement&#xD;
Antibiotic local prophylaxis with medicated calcium sulfate beads: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection</description>
          </group>
        </group_list>
        <measure>
          <title>Partipants Achieving a Lower Hip or Knee Periprosthetic Joint Infection Rate With Local Versus Conventional Intravenous Antibiotic Prophilaxys, Measured With CRP, ERS in Serum and Sinovial Fluid Leukocytes , Over the 12-week Observation Period.</title>
          <description>Acute periprosthetic knee or hip infection was determined using CRP and ESR serum biomarkers, which are the most commonly published serum biomarkers in periprosthetic joint infection literature. The cut off point for CRP was considered 93mg/L and 44mm/hr for ESR. The serum biomarker sample was taken and evaluated on day 5 and weeks 4, 8 and 12. Leukocytes in synovial fluid are among the criteria for definition of periprosthetic joint infection with a cut off point above 12,800 cells/µL and were only included if serum biomarkers were elevated.</description>
          <population>Patients who agreed to join the study and who met the selection criteria. After 3 moths presents or not periprosthetic joint infection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>With Periprosthetic Joint infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without periprosthetic infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0.- There is no significant difference in the incidence of periprosthetic infection in patients with non-modifiable risk factors and prophylactic application of antibiotic loaded calcium sulfate compared with patients without prophylactic treatment with calcium sulfate.&#xD;
The presence of periprosthetic infection in both groups was evaluated by chi2 and Lambda tests for dichotomous nominal and qualitative variables with longitudinal direction and relative risk factor test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.168</ci_upper_limit>
            <estimate_desc>For the Relative risk the control Study group was the numerator and control group denominator. In the 2X2 contingency table the rows correspond to groups and columns for the presence or abscence of periprosthetic infection.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay as an Indicator of the Hospital Economic Burden</title>
        <description>The length of stay is an important indicator of efficiency and hospital economic burden. The reduction in number of hospitalization days results in lower risk of infection and less medication side effects and decreased need of hospital supplies. The difference in the average days of hospitalization between both groups indirectly represents the economic cost spent by the hospital.</description>
        <time_frame>Surgical procedure day to hospital discharge.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement&#xD;
Classical parenteral antibiotic prophylaxis: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection. 750 mgs of Intra Venous Ceftriaxone 20 minutes before joint replacement surgery and every 8 hours for 24 hours</description>
          </group>
          <group group_id="O2">
            <title>Calcium Sulfate Study Group</title>
            <description>Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement&#xD;
Antibiotic local prophylaxis with medicated calcium sulfate beads: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection. 3g of vancomycin mixed with Stimulan Kit (Biocomposites Ltd, United Kingdom) which includes 10 cc (20 g) of calcium sulfate hemihydrate powder</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay as an Indicator of the Hospital Economic Burden</title>
          <description>The length of stay is an important indicator of efficiency and hospital economic burden. The reduction in number of hospitalization days results in lower risk of infection and less medication side effects and decreased need of hospital supplies. The difference in the average days of hospitalization between both groups indirectly represents the economic cost spent by the hospital.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.25" spread="10.06"/>
                    <measurement group_id="O2" value="4.6" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lenght of stay was the variable that compares both groups and was a continous variable (t-test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>The statistical test of t was performed for the variable length of hospital stay, finding a significant difference with a p value &lt; 0.01</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months after surgical procedure.</time_frame>
      <desc>Adverse mortality events from all causes, serious or other (non-serious) adverse events were monitored but none observed in the 3 months after the surgical procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Calcium Sulfate Study Group</title>
          <description>Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement&#xD;
Antibiotic local prophylaxis with medicated calcium sulfate beads: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection. 3g of vancomycin mixed with Stimulan Kit (Biocomposites Ltd, United Kingdom) which includes 10 cc (20 g) of calcium sulfate hemihydrate powder</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement&#xD;
Classical parenteral antibiotic prophylaxis: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection. 750 mgs of Intra Venous Ceftriaxone 20 minutes before joint replacement surgery and every 8 hours for 24 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julio Carlos Vélez de Lachica, Head of the orthopedics department at Regional Hospital Tlalnepantla</name_or_title>
      <organization>ISSEMyM Instituto de Seguridad Social del Estado de Mexico y Municipios</organization>
      <phone>5526269200 ext 2100</phone>
      <email>activeknee@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

